Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs DexCom, Inc. — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.83, while DexCom, Inc. trades at $89.97 (market cap $33.79B). The key difference: DexCom, Inc. is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | DXCM | |
|---|---|---|
52-Week High | $49.91 | $89.53 |
52-Week Low | $47.57 | $54.84 |
Market Cap | — | $33.79B |
Sector | — | Health |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.
Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
